A trial judge’s decision to establish a litigationwide cutoff date for when claims should have been brought against Janssen Pharmaceuticals over the drug Risperdal fails to apply standard discovery-rule principles, unfairly placing hundreds of cases at risk of dismissal, an attorney representing numerous plaintiffs told a Pennsylvania Superior Court panel Tuesday.
Kline & Specter attorney Charles “Chip” Becker told the three-judge panel the issue directly affects 275 cases that have been dismissed as a result of Supervising Judge Arnold New’s application of the statute of limitations in Risperdal litigation. Becker said it could also impact hundreds more in the Philadelphia Court of Common Pleas, where more than 2,000 cases are pending.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
